Intra-Cellular Therapies (NASDAQ:ITCI)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued on Thursday, The Fly reports. They currently have a $29.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $26.00. Cantor Fitzgerald’s target price indicates a potential upside of 115.29% from the stock’s current price.
A number of other equities analysts have also weighed in on the stock. ValuEngine lowered shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Thursday, January 24th. BidaskClub lowered shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Intra-Cellular Therapies presently has an average rating of “Hold” and a consensus target price of $27.60.
ITCI stock opened at $13.47 on Thursday. The stock has a market cap of $742.43 million, a PE ratio of -4.74 and a beta of 1.39. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.59 and a quick ratio of 9.59. Intra-Cellular Therapies has a 52 week low of $10.21 and a 52 week high of $23.64.
In other Intra-Cellular Therapies news, Director Christopher D. Alafi purchased 100,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were purchased at an average cost of $12.56 per share, for a total transaction of $1,256,000.00. Following the completion of the transaction, the director now owns 750,106 shares of the company’s stock, valued at approximately $9,421,331.36. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 17.40% of the company’s stock.
A number of large investors have recently bought and sold shares of ITCI. Samlyn Capital LLC boosted its holdings in Intra-Cellular Therapies by 64.2% in the 4th quarter. Samlyn Capital LLC now owns 1,266,138 shares of the biopharmaceutical company’s stock valued at $14,421,000 after purchasing an additional 494,918 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in Intra-Cellular Therapies by 19.0% in the 1st quarter. Wasatch Advisors Inc. now owns 2,361,619 shares of the biopharmaceutical company’s stock valued at $28,765,000 after purchasing an additional 377,561 shares during the last quarter. Norges Bank acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at about $3,759,000. General American Investors Co. Inc. acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at about $3,416,000. Finally, Rhenman & Partners Asset Management AB boosted its holdings in Intra-Cellular Therapies by 43.9% in the 1st quarter. Rhenman & Partners Asset Management AB now owns 949,833 shares of the biopharmaceutical company’s stock valued at $11,569,000 after purchasing an additional 289,851 shares during the last quarter. Institutional investors own 71.11% of the company’s stock.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Featured Article: Using other technical indicators with support levels
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.